Pacific Biosciences Of California (PACB) Income from Continuing Operations (2010 - 2026)
Pacific Biosciences Of California (PACB) posted quarterly Income from Continuing Operations of 8275000.0 for Q1 2026, up 98.06% year-over-year from 4178072.14 in Q1 2025, and up 79.5% quarter-over-quarter from 40371000.0 in Q4 2025.
Pacific Biosciences Of California (PACB) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Pacific Biosciences Of California's Income from Continuing Operations history runs 17 years deep, the most recent figure standing at 8275000.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations rose 98.06% year-over-year to 8275000.0; the TTM figure through Mar 2026 stood at 128576000.0 (up 80.45% YoY), while the FY2025 annual figure was 546376000.0, down 76.34% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 8275000.0, up from 40371000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 2371000.0 in Q4 2024, with the low at 426075000.0 in Q1 2025.
- The 5-year median for Income from Continuing Operations is 71394000.0 (2022), against an average of 87381470.59.
- The sharpest annual moves came in 2024 and 2025: Income from Continuing Operations soared 102.89% in 2024, then slumped 1802.7% in 2025.
- Pacific Biosciences Of California's Income from Continuing Operations stood at 84384000.0 in 2022, then gained by 2.8% to 82018000.0 in 2023, then jumped by 102.89% to 2371000.0 in 2024, then plunged by 1802.7% to 40371000.0 in 2025, then jumped by 79.5% to 8275000.0 in 2026.
- Business Quant data shows PACB's Income from Continuing Operations at 8275000.0 in Q1 2026, 40371000.0 in Q4 2025, and 38000000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 200.20 Bn | 194.60 Bn | 7.27 Bn | 928.00 Mn |
| 2 | Stryker | 129.69 Bn | 126.21 Bn | 4.50 Bn | 1.28 Bn |
| 3 | Medtronic | 120.14 Bn | 110.92 Bn | 6.41 Bn | 1.26 Bn |
| 4 | Boston Scientific | 74.16 Bn | 73.62 Bn | 3.85 Bn | 905.00 Mn |
| 5 | Edwards Lifesciences | 52.68 Bn | 48.43 Bn | 1.35 Bn | 241.40 Mn |
| 6 | Dexcom | 34.57 Bn | 32.62 Bn | 830.00 Mn | 249.10 Mn |
| 7 | GE HealthCare Technologies | 34.09 Bn | 31.98 Bn | 2.18 Bn | 574.00 Mn |
| 8 | Koninklijke Philips | 26.49 Bn | 23.17 Bn | 4.55 Bn | 1.04 Bn |
| 9 | Steris | 23.19 Bn | 22.70 Bn | 684.20 Mn | 201.00 Mn |
| 10 | Pacific Biosciences Of California | 400.74 Mn | 163.87 Mn | 12.64 Mn | -44.74 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -44.74 Mn |
| Mar 31, 2026 | -8.28 Mn |
| Dec 31, 2025 | -40.37 Mn |
| Sep 30, 2025 | -38.00 Mn |
| Jun 30, 2025 | -41.93 Mn |
| Mar 31, 2025 | -426.08 Mn |
| Dec 31, 2024 | 2.37 Mn |
| Sep 30, 2024 | -60.73 Mn |
| Jun 30, 2024 | -173.32 Mn |
| Mar 31, 2024 | -78.18 Mn |
| Dec 31, 2023 | -82.02 Mn |
| Sep 30, 2023 | -66.87 Mn |
| Jun 30, 2023 | -69.83 Mn |
| Mar 31, 2023 | -88.02 Mn |
| Dec 31, 2022 | -84.38 Mn |
| Sep 30, 2022 | -76.97 Mn |
| Jun 30, 2022 | -71.39 Mn |
| Mar 31, 2022 | -81.50 Mn |
| Dec 31, 2021 | -69.33 Mn |
| Jun 30, 2021 | -88.19 Mn |